Clinical results of Hancock II versus Hancock Standard at long-term follow-up  by Valfrè, Carlo et al.
C
a
C
S
Valfrè et al Surgery for Acquired Cardiovascular Diseaselinical results of Hancock II versus Hancock Standard
t long-term follow-up
arlo Valfrè, MD,a Giulio Rizzoli, MD, FETCS,b Claudio Zussa, MD,c Paolo Ius, MD,a Elvio Polesel, MD,calvatore Mirone, MD,a Tomaso Bottio, MD,b and Gino Gerosa, MDb
O
v
M
p
a
m
I
m
d
p
R
o
3
2
a
h
b
h
H
A
S
e
C
p
d
T
H
fi
a
i
y
s
a
d
t
A
CDSupplemental material is
available online.
From the Cardiac Surgery Unit, Cà Fon-
cello Hospital of Treviso,a Treviso, Italy;
Cardiac Surgery Unit, University of
Padova,b Padova, Italy; and Cardiac Sur-
gery Unit, Umberto I° Hospital of Venice,c
Venice, Italy.
Supported by Ministry of University and
Scientific Research, 2003 (project “Meta-
analisi degli studi comparativi dei risultati a
distanza delle protesi biologiche e mec-
caniche” [Meta-analysis of the studies com-
paring long-term results of biologic and
mechanical prostheses]).
Received for publication Oct 28, 2005; re-
visions received Feb 10, 2006; accepted for
publication March 21, 2006.
Address for reprints: Giulio Rizzoli, MD,
FETCS, Cardiochirurgia, Via Giustiniani
2 35128, Padova, Italy (E-mail: giulio.
rizzoli@unipd.it).
J Thorac Cardiovasc Surg 2006;132:595-601
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
Drs Valfrè, Mirone, Rizzoli, Gerosa, Bottio, and
Salvador (left to right)r
doi:10.1016/j.jtcvs.2006.03.062bjective: We performed a multi-institutional study to compare the long-term structural
alve deterioration of isolated Hancock Standard versus Hancock II bioprostheses.
ethods: From 1983 to 2002, 714 Hancock Standard and 1293 Hancock II bio-
rostheses were implanted at hospitals of the Venetian territory (Padova, Treviso,
nd Venice). Follow-up on January 1, 2003, included 14,749 patient-years with a
edian of 12 years and was 96% complete: 115 Hancock Standard and 53 Hancock
I bioprostheses were at risk at 15 years. The 2 series were nonconcomitant, and
any covariates differed (Table 1). Survival was analyzed with Cox analysis, and
urability was analyzed with Weibull analysis. Balancing analysis with the logistic
ropensity score model was performed.
esults: Perioperative mortality was 6% in Hancock II and 12% in Hancock Standard
perations. The overall unadjusted 15-year survival was identical (39.7% 2.3% vs
9.9%  2.4%, respectively), but age-adjusted survival at 15 years was 46% versus
5% (P .001). Late survival was unrelated to the prosthetic model, whereas it was
dversely affected by older age, previous operations, aortic regurgitation, male sex,
igher New York Heart Association class, atrial fibrillation, and coronary artery
ypass grafting. In Hancock II patients aged 65 years and older, the cumulative
azard of structural valve deterioration at 15 years was 6%, versus 17.5% in
ancock Standard patients. In younger patients, it was 18% and 37%, respectively.
nalysis of 541 propensity-balanced patients showed a hazard ratio of the Hancock
tandard prosthesis of 2 and a risk reduction of older age of approximately 10%
very 10 years.
onclusion: After balancing risk factors and calibrating age effects, Hancock II
ropensity-matched bioprostheses showed similar survival but definitely increased
urability.
he Hancock Standard (HST) porcine prosthesis was one the most commonly
used biologic valve substitutes in the 1970s. Like other first-generation
bioprostheses, it had the disadvantage of limited durability. In 1982, the
ancock II (HII) valve was introduced with a lower implant profile, a 2-stage
xation process (initial low pressure and late high pressure), and a calcium-retarding
gent (sodium dodecylsulfate). Contemporarily, surgeons revised their clinical
ndications and therefore limited bioprosthetic use to older patients (65 or 70
ears) with a lower life expectancy and, presumably, insufficient time to develop
tructural valve deterioration (SVD). Age-related natural death, premature death,
nd valve replacement for other causes confound the estimate of improvement of
urability.
With the aim of verifying the durability improvement of this second-generation
issue valve and its relationship with operative age and valve position, the clinical
esults of HII prostheses inserted at Padova, Treviso, and Venice were propensity-
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CDatched and compared with the results of a historic series of
rst-generation HST prostheses implanted in the 1970s at
he University of Padova.
atients and Methods
tudy Group
he study group included 1931 patients who received 2007 iso-
ated aortic (n  998) or mitral (n  1009) prostheses. Patients
ith tricuspid plastic repairs were included. There were 1293 HII
nd 714 HST valves. Twenty-seven HST patients received a sec-
nd HST, and 30 received an HII prosthesis. Seventeen HII
atients received a second HII, and 2 patients received a third one.
reviso contributed 984 records, Venezia 129, and Padova 894.
ll the HST valves were inserted in Padova, and 77% of the HII
alves were inserted in Treviso; 62% of the mitral valves were
perated on in Padova, and 65% of the aortic valves were operated
n in Treviso. HST valves were implanted from 1970 to 1984, and
II valves were implanted from 1983 to 2002. The mean age was
8 12 years in HST patients (median, 49 years) and 67 8 years
n the HII group (median, 69 years). Covariate distribution is
ummarized in Table 1.
ollow-up
ollow-up was conducted trough mail or telephone interview,
as closed on January 1, 2003, and was 96% complete. The
otal follow-up included 14,749 patient-years: HII patients had a
otal follow-up of 8520 patient-years, and HST patients had a total
ollow-up of 6229 patient-years, with a median of 12 years in both
eries. Data analysis is reported at 15 years, with 53 HII and 115
ST patients at risk.
perative Technique
mplantation used pledgeted sutures in a subannular position. The
hoice of prosthetic size was according to patient size. A single 19
m prosthesis and 29 label 21 mm prostheses were used. The
edian valve label size was 23 mm in aortic HII and 25 mm in
ST (P  .017), and it was 29 mm in mitral HII and 31 mm in
ST (P  .08). The HST mean clamp time was 45  19 minutes,
nd cardiopulmonary bypass time was 72  33 minutes—signif-
cantly shorter (P  .001) than in the HII series (79  29 minutes
nd 112  41 minutes, respectively).
utcomes
he focus of the study was mortality, reoperation, and SVD,
ecorded according to guidelines set forth by the American Asso-
iation for Thoracic Surgery.1 Other valve-related events wer
Abbreviations and Acronyms
AF  atrial fibrillation
HII  Hancock II
HST  Hancock Standard
NYHA  New York Heart Association
SVD  structural valve deteriorationonsidered secondary. r
96 The Journal of Thoracic and Cardiovascular Surgery ● Septetatistical Analysis
atients were censored when the valve was replaced, unless they
ied at reoperation. Stata for Windows was used for statistical
nalyses (Stata Corp, College Station, Tex).
nivariate Analysis
ifferences in prognostic variables between HST and HII valves
ere evaluated by t tests for continuous variables and by the Fisher
xact test for categorical variables. Distributional differences were
valuated by nonparametric bootstrapped quantile regression anal-
sis. Time-related events were analyzed with the Kaplan-Meier
ethod. Secondary valve-related events are reported as linearized
ABLE 1. Prevalence of covariates
ovariates
Hancock
Standard
(714 valves)
Hancock II
(1293 valves) P value
ale sex 340 (48%) 803 (62%) .0001
ge, y (mean  SD) 47.8  11.9 67.5  8.2 .0001
YHA class .0001
I 0 36 (3%)
II 19 (3%) 506 (39%)
III 580 (81%) 536 (41%)
IV 108 (15%) 184 (14%)
ardiogenic shock 6 (0.8%) 32 (3%) .01
ndocarditis 23 (3%) 48 (4%) .5
iabetes 14 (2%) 53 (4%) .009
ypertension 39 (5.5%) 96 (7%) .04
hronic renal failure 2 (0.3%) 43 (3%) .0001
mergent /urgent procedure 10 (1.4%) 65 (5%) .0001
revious cardiac operation 94 (13%) 160 (12%) .6
itral valve position 525 (73%) 484 (37%) .0001
ortic valve position 189 (26%) 809 (63%) .0001
alve pathology
Rheumatic 498 (70%) 211 (16%) .0001
Degenerative 100 (14%) 397 (31%) .0001
Prosthetic pathology 50 (7%) 119 (9%) .08
revious SVD episode 16 (2%) 38 (3%) .3
tenosis 170 (24%) 405 (31%) .001
ncompetence 198 (28%) 494 (38%) .0001
oderate stenosis and
incompetence
345 (48%) 382 (10%) .0001
inus rhythm 276 (39%) 907 (70%) .0001
trial fibrillation or flutter 433 (61%) 343 (27%) .0001
acemaker 4 (0.6%) 29 (2%) .005
oronary artery disease 28 (4%) 343 (25%) .0001
ritical coronary disease 18 (2%) 273 (21%) .0001
oronary artery bypass
graft
24 (3%) 317 (25%) .0001
scending aorta
replacement
14 (2%) 110 (8.5%) .0001
rossclamp time (min) 45.2  19.2 79.1  29.5 .0001
ardiopulmonary bypass
time (min)
72  32.6 112  40.8 .0001
YHA, New York Heart Association.ates for practical reasons.
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A
CDActual freedom from SVD and from reoperation was evaluated
ith the method previously described by Grunkemeier and col-
eagues.2 A simultaneous decrement analysis of the events surv
ith the original prosthesis, death, and SVD was performed by
sing the algorithm of Anderson.3
ultivariable Analysis
he preoperative variables tested for their univariate and multiva-
iable association with the outcomes were valve position (mitral or
ortic), demographics (age and sex), valve pathology (insuffi-
iency, mixed lesion, stenosis, active endocarditis, healed endo-
arditis, rheumatic, degenerative, ischemic, prosthetic pathology,
ther pathology, precedent SVD event, and precedent Hancock
alve insertion), clinical (New York Heart Association [NYHA]
lass, atrial fibrillation, and pacemaker), operative (operative date,
scending aorta replacement, coronary artery bypass grafting, left
nternal thoracic artery use, emergency operation, and operative
enter), and associated risk factors (hypertension, chronic renal
ailure, diabetes, previous cardiac operation, coronary artery dis-
ase, and critical coronary disease).
Late survival was evaluated by means of a Cox semiparametric
odel, and SVD was evaluated by means of Weibull parametric
odel. Variable choice, by means of a stepwise backward and
orward algorithm (P to enter, .10; P to retain, .20), was supported
y bootstrap analysis with 1000 repetitions of randomly selected
amples with replacement. Calibration of the operative age vari-
ble was obtained by plotting the coefficients of SVD probability
n 6 age groups of approximately equal size versus several age
ransformations and choosing the one with the best linearizing
roperty. Propensity score analysis4 was performed to identif
locks of HII and HST valves with the same mean score and with
alanced prevalence of all covariates (P  .01).
esults
hirty-day Mortality
total of 89 HST and 76 HII patients died, with a surgical
isk of 12.5% (95% confidence interval, 10%-15%) versus
% (95% confidence interval, 4.6%-7.3%).
verall Mortality
ST mortality was 392 patients, and HII mortality was 477
atients. Unadjusted survival of HST versus HII was 73%
.7% versus 79%  1.2% at 5 years, 59%  1.9% versus
8%  1.7% at 10 years, and 40%  2.3% versus 39.7% 
.4% at 15 years (P  .46). Age-adjusted HST survival at
5 years was 25% versus 46% (P .001), but the difference
as exclusively related to the 30-day mortality, as shown in
igure E1.
ultivariate Survival Analysis
ootstrapped multivariable Cox analysis of survival deter-
inants of the perioperative survivors (Table E1) was i
ified 99.9% of the time (bootstrap drawings). It detailed a
3% decreased risk for patients up to 45 years, a decreased
isk of 29% up to 60 years, a 26% increased risk up to 70
ears, and an 84% increased risk for more than 70 years. S
The Journal of Thoraciche incremental risk of NYHA class was identified 100% of
he times, with a hazard ratio of 2 for NYHA III, a hazard
f 3.5 for NYHA IV, and a hazard of 3.7 if cardiogenic
hock was also present. Endocarditis was selected in 97% of
rawings, with a hazard ratio of 3. Male sex, with a 1.5
azard ratio; coronary artery disease, with a 1.4 hazard
atio; and atrial fibrillation, with a 1.3 hazard ratio, were
elected in 99%, 84%, and 53% of the drawings, respec-
ively. A more recent operative year decreased the risk of
eath of 3% per year in 56% of the drawings.
alve-related Adverse Events
ST valves had 91 embolic episodes, versus 123 for the HII;
1 hemorrhagic events, versus 49; 25 endocarditis events,
ersus 37; 4 thrombosis events, versus 4; and 19 perivalvu-
ar leaks, versus 5. The severity of HII events is detailed in
his issue.5 Linearized rates are summarized in Table 
nd, with the exception of leaks, were similar between
odels and were within the limits reported by the review of
he literature.6 Nonetheless, valve-related mortality an
orbidity were significantly higher in the HST group as a
esult of a significantly larger number of reoperations.
eoperation
ighty HII and 340 HST patients underwent reoperation.
VD was the first cause of reoperation in 51 HII cases and
93 HST cases. The second most common cause was en-
ocarditis (21 HII and 21 HST cases). Overall actuarial
reedom from reoperation of the HII was 97.7%  0.5% at
years, 92.9%  1.1% at 10 years, and 76.3%  3.3% at
5 years. In HST patients, it was 93.8%  1.0%, 69.4% 
.1%, and 35.9%  2.4%, respectively (P  .001).
tructural Valve Deterioration
ioprosthetic valve dysfunction due to structural valve de-
erioration (SVD) occurred in 57 HII (21 aortic and 36
itral) and 313 HST (80 aortic and 233 mitral) patients. For
II in the mitral position, there were 27 events in patients
ounger than 65 years and 9 SVD episodes in older patients.
n the aortic position, there were 15 events in patients
ounger than 65 years and 6 events in older patients. For
ST in the mitral position, there were 231 events in patients
ounger than 65 years and 2 events in older patients. In the
ortic position, there were 77 and 3 events, respectively.
he relationship of age versus the probability of SVD,
btained by stratifying patients in 6 groups of equal size,
as curvilinear, with a lower probability of the event as the
perative age increased, and was linearized by an exponen-
ial transformation (Figure 1).
The overall actuarial freedom from SVD of HII versus
ST is shown in Figure 2, and freedom of patients 
VD younger than 65 years or 65 years or older is shown in
and Cardiovascular Surgery ● Volume 132, Number 3 597
F  in
T
d
w
e
r
o
y
p
a
r
w
(
y
r
i
b
p
1
o
7
o
p
Surgery for Acquired Cardiovascular Disease Valfrè et al
5
A
CDigures 3 and 4. Actual freedom from SVD is summarized
able 2.
Bootstrapped multivariable Weibull analysis in 100% of
raws identified older age as a powerful protective factor,
ith a risk reduction of 8.2% every 10 years. Given the
xponential relationship of SVD and age, the SVD hazard
atio was 3 times higher for patients younger than 45 years
f age and 2.4 times higher for patients younger than 60
ears. It was 0.62 to 70 years and 0.28 above 70 years.
Critical coronary artery disease and degenerative valve
athology were decremental risk factors identified in 89%
nd 81% of the bootstraps, respectively, with a hazard
eduction of 74% and 33%, respectively. Conversely, HST98 The Journal of Thoracic and Cardiovascular Surgery ● Septeas an incremental risk factor in 100% of the bootstraps
hazard ratio, 2.2), with a predicted median duration of 12
ears, versus 19 years for the HII. Hypertension (hazard
atio, 2.3) and mixed lesions (hazard ratio, 1.27) were
ncremental risk factors selected in 74% and 81% of the
ootstraps, respectively (Table 3).
Multiple decremental analysis of 65-year-old or older
atients operated on with the HST valve showed that after
5 years, their actual probability of being alive with the
riginal prosthesis was 6%, their death probability was
6%, and the SVD probability was 18%. In 65-year-old or
lder patients operated on with HII valves, the 15-year
robability of being alive with the original prosthesis was
Figure 1. Continuous age calibration: operative
age was stratified into 6 groups of equal size,
and the SVD risk coefficient (Cox analysis) was
plotted against the median age of each group
(circles). The best age transformation that lin-
earized the circle distribution was the exponen-
tial of age. SVD, structural valve deterioration.
Figure 2. Actuarial freedom from SVD for the
Hancock II and Standard valves with 95% confi-
dence intervals (C.I). The Weibull predicted
probability curves, adjusted for operative age
and other covariates in Table 3, are overlaid.
SVD, structural valve deterioration.mber 2006
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A
CD0%, the death probability was 64%, and the SVD proba-
ility was 6%.
Propensity score analysis identified 5 blocks of HII and
ST valves with the same mean propensity score and bal-
ncing of all covariates. These blocks add up to 541 valves
255 HST and 286 HII), with 81 events in the HST group
nd 26 in the HII group. The ratio of HST to HII was
69:165 in the mitral position and 86:121 in the aortic
osition. Bootstrapped Weibull analysis confirmed the in-
remental SVD risk of HST, with a hazard ratio of 2. Older
ge was a significant decremental risk factor, with an ap-
roximately 10% decrement every 10 years (Table 4).
iscussion
orcine prostheses were introduced into clinical use by
arpentier and colleagues7 in the 1960s, and the comm-
ially available HST valve was immediately accepted inThe Journal of Thoracicadova as an ideal substitute in young or middle-aged
atients and fertile women.8 Many valves (n  583) had
lready been inserted in all positions before the disquieting
eports of early prosthetic degeneration in children by Geha
nd associates9 and Silver and colleagues.10 The actuarial
VD freedom of our HST valves, inserted in patients with
mean operative age of 48 years, was 38% at 15 years. This
s similar to the results reported by several groups.11-13 It is
herefore representative of the average durability of this
rosthesis, and we consider this historical experience very
seful to assess the advantage of the modifications of the
econd-generation HII prosthesis.
Tissue valve failures were summarized by Valente and
ssociates14 as primary failure (due to dystrophic calcificati
hrombosis, fibrous tissue overgrowth, primary tears, cuspal
ematomas, and stent-post bending) or secondary failure (due
o endocarditis and paravalvular leak). Calcification was the
Figure 3. Actuarial freedom from SVD for the
Hancock (Hck) II and Standard valves in patients
operated on at ages younger than 65 years. SVD,
structural valve deterioration.
Figure 4. Actuarial freedom from SVD for the
Hancock (Hck) II and Standard valves in patients
operated on at ages 65 years or older. SVD,
structural valve deterioration.and Cardiovascular Surgery ● Volume 132, Number 3 599
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A
CDain factor (88%) that influenced long-term durability; there-
ore, HII improvement was directed toward maintenance of the
atural collagen crimps, with low or zero pressure fixation, the
ddition of a dodecylsulfate (T6) calcium-retarding agent, and
stent with a lower implant profile.
Use of second-generation prostheses was prudentially
estricted to older ages because of the wisdom that the older
he patient, the lower the risk of having a reoperation,15 a d
ecause the “worldwide surgical pendulum had swung back
oward favouring mechanical valves in the majority of pa-
ients.”16 It is obvious that to verify the claimed prost
mprovements, their use should be liberalized to relatively
ounger patients to permit age-matched comparisons, but
his cannot be done, for ethical reasons. It is also obvious
hat actual probabilities must be calculated, because actuar-
al estimates are severely biased by the censoring of dead
atients.2 Despite the reversed bias due to the introduc
f sensible and specific echocardiography, HII valves
howed 97% actual freedom from SVD at 10 years and 88%
reedom at 15 years, with a significant improvement com-
ared with the 64% actual SVD freedom of our HST series.
he actual 15-year freedom from SVD of our HII seri5 is
imilar to those recently reported by two large series of HII
alves17,18 and seems superior to two large series of -
ardial valves,19,20 being representative of the average p-
ormance of second-generation porcine prostheses.
The HII and HST series are not concomitant, and patient
haracteristics differ largely. In a time span of 3 decades,
heumatic mitral disease has been dramatically reduced, and
here has been an increase of degenerative aortic stenosis of
ABLE 2. Actual freedom from SVD
ariable
Hancock Standard
5 10
VD 98.1 0.5 (495)* 82.2 1.5 (302)
f operative age 65 y 98 0.5 (434) 81.8  1.5 (266)
f operative age 65 y 99.0 0.98 (61) 86.7.1  6.2 (36) 8
Parentheses indicate number of patients at risk. SVD, structural valve d
ABLE 3. Weibull analysis of 2007 patients
isk factors HR SE
ancock Standard 2.2 0.36
xponential of age 0.42 0.05
ritical (70%) CAD 0.26 0.14
ypertension 2.3 0.89
ixed stenosis/incompetence 1.27 0.14
egenerative valve pathology 0.67 0.11
n_P 1.04 0.03
R, Hazard ratio; CI, confidence interval; CAD, coronary artery disease; ln_
n 1000 repetitions of the multivariable backward stepwise model (P to remain,
00 The Journal of Thoracic and Cardiovascular Surgery ● Septehe elderly and of concomitant coronary artery disease21 and
oronary artery bypass grafting. Operative techniques have
mproved in many details, with a decrease of operative
ortality from 13% to less than 6%. The early surgeon had
o use skill and surgical dexterity to offset the limitations
mposed by cardiac ischemia, as shown by the significantly
horter clamp times of the HST. Adjusting for age differ-
nces, late mortality, valve-related mortality, and complica-
ions, rates were identical in the compared prostheses. The
nly differences were a significant reduction of the dehis-
ence rate and the SVD-related reoperation rate.
In the presence of a moving target, despite multivariable
nalysis adjustment, it is difficult to resist the accusation
hat we are comparing apples with oranges22; therefore, 
ropensity analysis was applied to balance the patients of
he two series. Six groups of patients with equal propensity
cores and balanced characteristics were identified, for a
otal of 541 patients with an almost equal proportion of HII
nd HST valves.
The principal confounder in the analysis of SVD events is
he patient’s age at operation, so the analysis must convince the
eader that the SVD reduction is due to valve improvement and
ot to age differences between series. In this respect, we had
o cope with a 20-year age difference between series, which
ecreased to 5 years by propensity matching, and with the
onlinear relationship of age and SVD probability. This
equired a calibration (linearizing transformation) of the age
ffect to avoid fitting of the residuals from any age-related
ariable, such as the prosthetic type.
Follow-up (y)
Hancock II
15 5 10 15
 1.8 (114) 100 (763) 97.0 0.7 (295) 88.3  1.7 (53)
 1.9 (102) 99.7  0.3 (259) 95.5  1.3 (140) 82.5  2.7 (37)
 6.8 (12) 100 (504) 98.3  .6 (155) 94 1.9 (16)
ration.
P > |z| 95% CI Bootstrap*
.001 1.59-3.06 100%
.001 0.32-0.55 100%
.010 0.092-0.72 89%
.024 1.11-4.94 74%
.029 1.02-1.57 81%
.021 0.47-0.94 84%
.001 0.97-1.11
tural logarithm of the shape parameter. *Percentage of variable inclusion63.5
62.6
3.3.28
7
P, na
.20; P to enter, .19).
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A
CDThe durability of the HST was similar in the aortic and
itral (63% vs 64% ) positions. Conversely, the durability
f the HII prosthesis was apparently better in the aortic position
92% vs 85%). This difference was observed by David and
ssociates17 but was not significant in our multivariable anal-
sis of the entire series or in propensity-matched patients. In
atients 65 years or older, the actual probability of valve
egeneration at 15 years was only 6%, and the probability of
eing alive with the original prosthesis was 30%.
We conclude that there is indeed a durability improve-
ent of the HII valve, not entirely explained by use in an
lderly population, that may be attributed to its technologic
dvancements over the first-generation porcine valves. This
onsideration would encourage relaxation of age limits for
ts use, particularly in the aortic position.5
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CDFigure E1. Age-adjusted survival of Hancock II
and Hancock Standard valves.
ABLE E1. Cox analysis of operative survivors
Risk factor HR 95% CI P value Bootstrap*
Natural log of age 5.68 2.76-10.9 .0001 100%
Male sex 1.55 1.32-1.83 .0001 100%
Coronary artery disease 1.29 1.23-1.42 .018 63.9%
NYHA class 1.35 1.20-1.53 .0001 99.9.0%
Atrial fibrillation 1.30 1.19-1.49 .002 87.5%
Prosthetic pathology 1.56 1.31-1.95 .0001 93.6%
Operative year 0.975 0.96-0.985 .0001 91.1%
R, Hazard ratio; CI, confidence interval; NYHA, New York Heart Association. *Percentage of variable inclusion in 1000 repetitions of multivariable
ackward stepwise model (P to remain, .20; P to enter, .19).
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Valfrè et al Surgery for Acquired Cardiovascular DiseaseABLE E2. Secondary events, linearized rates
vent Time at risk Events Rate % SE P value
ehiscence
Hancock II 8511 5 0.035 0.03
Hancock Standard 6257 19 0.27 0.07 .0001
mbolism
Hancock II 8140 123 1.5 0.14
Hancock Standard 5796 91 1.6 0.16 .81
ndocarditis
Hancock II 8495 37 0.39 0.07
Hancock Standard 6244 25 0.38 0.08 .78
emorrhage
Hancock II 8371 49 0.58 0.08
Hancock Standard 6136 41 0.65 0.07 .49
alve thrombosis
Hancock II 8516 4 0.035 0.02
Hancock Standard 6257 4 0.048 0.03 .50
alve-related M&M
Hancock II 7963 340 4.3 0.23
Hancock Standard 5594 462 8.3 0.38 .0001&M, Morbidity and mortality.
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